Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data
S Benzekry, M Grangeon, M Karlsen, M Alexa… - Cancers, 2021 - mdpi.com
Simple Summary We studied determinants of response to immune-checkpoint inhibition in
advanced non-small cell lung cancer patients. Specifically, we evaluated the association …
advanced non-small cell lung cancer patients. Specifically, we evaluated the association …
[HTML][HTML] Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
Background Gut microbiota composition can influence cancer immunotherapy response.
Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint …
Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint …
Is It Time to Integrate Frailty Assessment in Onconephrology?
Simple Summary There are an increasing number of older people living with kidney cancer
and/or cancer and kidney disease worldwide, sparking a wider discussion on the impact of …
and/or cancer and kidney disease worldwide, sparking a wider discussion on the impact of …
[HTML][HTML] Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors
DE Meyers, M Pasternak, S Dolter, HAI Grosjean… - JTO Clinical and …, 2023 - Elsevier
Introduction Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC
are difficult to extrapolate to real-world practice given the exclusion of patients with poor …
are difficult to extrapolate to real-world practice given the exclusion of patients with poor …
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers
JMB Pineda, RK Bradley - Elife, 2024 - elifesciences.org
Cancer immune evasion contributes to checkpoint immunotherapy failure in many patients
with metastatic cancers. The embryonic transcription factor DUX4 was recently characterized …
with metastatic cancers. The embryonic transcription factor DUX4 was recently characterized …
Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade
A Jain, S Zhang, RM Shanley, N Fujioka… - Cancer Immunology …, 2023 - Springer
Background We investigated the association of body mass index (BMI) modeled as a
continuous variable with survival outcomes in advanced non-small cell lung cancer …
continuous variable with survival outcomes in advanced non-small cell lung cancer …
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy
A De Giglio, A Leonetti, F Comito, DM Filippini… - Cancer Immunology …, 2024 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) are standard treatments for
advanced solid cancers. Resistance to ICIs, both primary and secondary, poses challenges …
advanced solid cancers. Resistance to ICIs, both primary and secondary, poses challenges …
Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
C Olsson Ladjevardi, A Koliadi, V Rydén… - Cancer …, 2023 - Wiley Online Library
Abstract Objective Checkpoint inhibitors (CPIs) are in widespread clinical use. Little is
known about which patients are at risk for developing toxicity. It is essential being able to …
known about which patients are at risk for developing toxicity. It is essential being able to …
[HTML][HTML] The Association of Immune-Related Adverse Events with the Efficacy of Atezolizumab in Previously Treated Advanced Non-Small-Cell Lung Cancer Patients …
F Marković, M Stjepanović, N Samardžić, M Kontić - Cancers, 2024 - mdpi.com
Simple Summary This study explores the association of immune-related adverse events
during atezolizumab therapy with better outcomes for patients with advanced non-small-cell …
during atezolizumab therapy with better outcomes for patients with advanced non-small-cell …
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
TJ Nielsen, MG Varga, CT Cronister, BZ Ring… - Cancer Immunology …, 2023 - Springer
Multiple targeted therapeutics have been approved by the FDA for mUC, including immune
checkpoint inhibitors (ICIs) and more recently targeted agents for both FGFR and Nectin-4 …
checkpoint inhibitors (ICIs) and more recently targeted agents for both FGFR and Nectin-4 …